6 O
ADVERSE O
REACTIONS O
EXCERPT O
: O
Most O
common O
adverse O
reactions O
( O
incidence O
> O
5 O
% O
) O
are O
upper O
respiratory O
tract O
infection O
, O
nasopharyngitis O
, O
injection O
site O
reactions O
( O
6.1 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Janssen O
Biotech O
, O
Inc O
. O
at O
1-800-JANSSEN O
( O
1-800-526-7736 O
) O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
clinical O
practice O
. O

The O
safety O
data O
described O
below O
are O
based O
on O
5 O
pooled O
, O
randomized O
, O
double-blind O
, O
controlled O
Phase O
3 O
trials O
in O
patients O
with O
RA B-Not_AE_Candidate
, O
PsA B-Not_AE_Candidate
, O
and O
AS B-Not_AE_Candidate
( O
Trials O
RA-1 O
, O
RA-2 O
, O
RA-3 O
, O
PsA B-Not_AE_Candidate
, O
and O
AS B-Not_AE_Candidate
) O
[ O
see O
Clinical O
Studies O
( O
14.1 O
, O
14.2 O
, O
and O
14.3 O
) O
] O
. O

These O
5 O
trials O
included O
639 O
control-treated O
patients O
and O
1659 O
SIMPONI-treated O
patients O
including O
1089 O
with O
RA B-Not_AE_Candidate
, O
292 O
with O
PsA B-Not_AE_Candidate
, O
and O
278 O
with O
AS B-Not_AE_Candidate
. O

The O
safety O
data O
in O
1233 O
SIMPONI-treated O
patients O
with O
ulcerative B-Not_AE_Candidate
colitis I-Not_AE_Candidate
from O
3 O
pooled O
, O
randomized O
, O
double-blind O
, O
controlled O
Phase O
2/3 O
trials O
are O
also O
described O
below O
( O
Trials O
UC-1 O
, O
UC-2 O
, O
and O
UC-3 O
) O
[ O
see O
Clinical O
Studies O
( O
14.4 O
) O
] O
. O

The O
proportion O
of O
patients O
who O
discontinued O
treatment O
due O
to O
adverse O
reactions O
in O
the O
controlled O
Phase O
3 O
trials O
through O
Week O
16 O
in O
RA B-Not_AE_Candidate
, O
PsA B-Not_AE_Candidate
and O
AS B-Not_AE_Candidate
was O
2 O
% O
for O
SIMPONI-treated O
patients O
and O
3 O
% O
for O
placebo-treated O
patients O
. O

The O
most O
common O
adverse O
reactions O
leading O
to O
discontinuation O
of O
SIMPONI O
in O
the O
controlled O
Phase O
3 O
trials O
in O
RA B-Not_AE_Candidate
, O
PsA B-Not_AE_Candidate
and O
AS B-Not_AE_Candidate
through O
Week O
16 O
were O
sepsis B-OSE_Labeled_AE
( O
0.2 O
% O
) O
, O
alanine B-OSE_Labeled_AE
aminotransferase I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
( O
0.2 O
% O
) O
, O
and O
aspartate B-OSE_Labeled_AE
aminotransferase I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
( O
0.2 O
% O
) O
. O

The O
most O
common O
adverse O
drug O
reactions O
leading O
to O
discontinuation O
through O
Week O
60 O
of O
the O
UC B-Not_AE_Candidate
trials O
in O
patients O
who O
received O
SIMPONI O
induction O
and O
100 O
mg O
during O
maintenance O
compared O
with O
patients O
who O
received O
SIMPONI O
induction O
and O
placebo O
during O
maintenance O
were O
tuberculosis B-OSE_Labeled_AE
( O
0.3 O
% O
vs O
0.6 O
% O
) O
and O
anemia B-OSE_Labeled_AE
( O
0.3 O
% O
vs O
0 O
% O
) O
, O
respectively O
. O

The O
most O
serious O
adverse O
reactions O
were O
: O
* O
Serious O
Infections B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Malignancies B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
Upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
and O
nasopharyngitis B-OSE_Labeled_AE
were O
the O
most O
common O
adverse O
reactions O
reported O
in O
the O
combined O
Phase O
3 O
RA B-Not_AE_Candidate
, O
PsA B-Not_AE_Candidate
and O
AS B-Not_AE_Candidate
trials O
through O
Week O
16 O
, O
occurring O
in O
7 O
% O
and O
6 O
% O
of O
SIMPONI-treated O
patients O
as O
compared O
with O
6 O
% O
and O
5 O
% O
of O
control-treated O
patients O
, O
respectively O
. O

Infections O
In O
controlled O
Phase O
3 O
trials O
through O
Week O
16 O
in O
RA B-Not_AE_Candidate
, O
PsA B-Not_AE_Candidate
, O
and O
AS B-Not_AE_Candidate
, O
infections B-OSE_Labeled_AE
were O
observed O
in O
28 O
% O
of O
SIMPONI-treated O
patients O
compared O
to O
25 O
% O
of O
control-treated O
patients O
. O

For O
serious O
infections B-OSE_Labeled_AE
, O
see O
the O
Warnings O
and O
Precautions O
section O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

In O
the O
controlled O
Phase O
2/3 O
trial O
of O
SIMPONI O
induction O
through O
Week O
6 O
in O
UC B-Not_AE_Candidate
, O
the O
rates O
of O
infections B-OSE_Labeled_AE
were O
similar O
in O
SIMPONI O
200/100 O
mg-treated O
patients O
and O
placebo-treated O
patients O
, O
or O
approximately O
12 O
% O
. O

Through O
Week O
60 O
, O
the O
incidence O
per O
patient O
year O
of O
infections B-OSE_Labeled_AE
was O
similar O
in O
patients O
who O
received O
SIMPONI O
induction O
and O
100 O
mg O
during O
maintenance O
compared O
with O
patients O
who O
received O
SIMPONI O
induction O
and O
placebo O
during O
the O
maintenance O
portion O
of O
the O
UC B-Not_AE_Candidate
trial O
. O

Demyelinating B-OSE_Labeled_AE
Disorders I-OSE_Labeled_AE
In O
the O
controlled O
Phase O
2/3 O
trial O
of O
SIMPONI O
induction O
through O
Week O
6 O
, O
no O
cases O
of O
demyelination B-NonOSE_AE
were O
observed O
in O
SIMPONI O
200/100 O
mg-treated O
patients O
or O
placebo-treated O
patients O
. O

Through O
Week O
60 O
, O
there O
were O
no O
cases O
of O
demyelination B-NonOSE_AE
in O
the O
SIMPONI O
100-mg O
group O
during O
maintenance O
. O

One O
case O
of O
CNS B-OSE_Labeled_AE
demyelination I-OSE_Labeled_AE
was O
observed O
in O
the O
placebo O
maintenance O
group O
in O
a O
patient O
who O
received O
SIMPONI O
400/200 O
mg O
during O
induction O
. O

Liver B-OSE_Labeled_AE
Enzyme I-OSE_Labeled_AE
Elevations I-OSE_Labeled_AE
There O
have O
been O
reports O
of O
severe O
hepatic B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
including O
acute B-OSE_Labeled_AE
liver I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
in O
patients O
receiving O
TNF O
blockers O
. O

In O
controlled O
Phase O
3 O
trials O
of O
SIMPONI O
in O
patients O
with O
RA B-Not_AE_Candidate
, O
PsA B-Not_AE_Candidate
, O
and O
AS B-Not_AE_Candidate
through O
Week O
16 O
, O
ALT B-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
> O
= O
5 O
* O
ULN O
occurred O
in O
0.2 O
% O
of O
control-treated O
patients O
and O
0.7 O
% O
of O
SIMPONI-treated O
patients O
and O
ALT B-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
> O
= O
3 O
* O
ULN O
occurred O
in O
2 O
% O
of O
control-treated O
patients O
and O
2 O
% O
of O
SIMPONI-treated O
patients O
. O

Since O
many O
of O
the O
patients O
in O
the O
Phase O
3 O
trials O
for O
RA B-Not_AE_Candidate
, O
PsA B-Not_AE_Candidate
, O
and O
AS B-Not_AE_Candidate
were O
also O
taking O
medications O
that O
cause O
liver B-NonOSE_AE
enzyme I-NonOSE_AE
elevations I-NonOSE_AE
( O
e.g. O
, O
NSAIDs O
, O
MTX O
) O
, O
the O
relationship O
between O
SIMPONI O
and O
liver B-NonOSE_AE
enzyme I-NonOSE_AE
elevation I-NonOSE_AE
is O
not O
clear O
. O

In O
Phase O
2/3 O
UC B-Not_AE_Candidate
trials O
, O
the O
incidence O
of O
ALT B-NonOSE_AE
elevations I-NonOSE_AE
> O
= O
5 O
* O
ULN O
was O
similar O
in O
SIMPONI-treated O
patients O
and O
placebo-treated O
patients O
, O
or O
approximately O
1 O
% O
, O
with O
an O
average O
duration O
of O
follow-up O
of O
46 O
weeks O
and O
18 O
weeks O
, O
respectively O
. O

ALT B-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
> O
= O
3 O
* O
ULN O
occurred O
in O
2.0 O
% O
of O
SIMPONI-treated O
patients O
compared O
with O
1.5 O
% O
of O
placebo-treated O
patients O
with O
an O
average O
duration O
of O
follow-up O
of O
46 O
weeks O
and O
18 O
weeks O
, O
respectively O
. O

Autoimmune O
Disorders O
and O
Autoantibodies O
In O
the O
controlled O
Phase O
3 O
trials O
in O
patients O
with O
RA B-Not_AE_Candidate
, O
PsA B-Not_AE_Candidate
, O
and O
AS B-Not_AE_Candidate
through O
Week O
14 O
, O
there O
was O
no O
association O
of O
SIMPONI O
treatment O
and O
the O
development O
of O
newly O
positive B-NonOSE_AE
anti I-NonOSE_AE
- I-NonOSE_AE
dsDNA I-NonOSE_AE
antibodies I-NonOSE_AE
. O

In O
Phase O
3 O
trials O
in O
RA B-Not_AE_Candidate
, O
PsA B-Not_AE_Candidate
, O
and O
AS B-Not_AE_Candidate
through O
1 O
year O
of O
follow-up O
, O
4.0 O
% O
of O
SIMPONI-treated O
patients O
and O
2.6 O
% O
of O
control O
patients O
were O
newly O
antinuclear B-OSE_Labeled_AE
antibody I-OSE_Labeled_AE
( I-OSE_Labeled_AE
ANA I-OSE_Labeled_AE
) I-OSE_Labeled_AE
- I-OSE_Labeled_AE
positive I-OSE_Labeled_AE
( O
at O
titers O
of O
1:160 O
or O
greater O
) O
. O

The O
frequency O
of O
anti B-NonOSE_AE
- I-NonOSE_AE
dsDNA I-NonOSE_AE
antibodies I-NonOSE_AE
at O
1 O
year O
of O
follow-up O
was O
uncommon O
in O
patients O
who O
were O
anti B-Not_AE_Candidate
- I-Not_AE_Candidate
dsDNA I-Not_AE_Candidate
negative I-Not_AE_Candidate
at O
baseline O
. O

Through O
Week O
60 O
of O
the O
UC B-Not_AE_Candidate
trials O
, O
3.5 O
% O
of O
patients O
who O
received O
SIMPONI O
induction O
and O
100 O
mg O
during O
maintenance O
were O
newly O
ANA B-OSE_Labeled_AE
- I-OSE_Labeled_AE
positive I-OSE_Labeled_AE
( O
at O
titers O
of O
1:160 O
or O
greater O
) O
compared O
with O
3.5 O
% O
of O
patients O
who O
received O
SIMPONI O
induction O
and O
placebo O
during O
the O
maintenance O
portion O
of O
the O
UC B-Not_AE_Candidate
trial O
. O

The O
frequency O
of O
anti B-OSE_Labeled_AE
- I-OSE_Labeled_AE
dsDNA I-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
at O
1 O
year O
of O
follow-up O
in O
patients O
who O
were O
anti B-Not_AE_Candidate
- I-Not_AE_Candidate
dsDNA I-Not_AE_Candidate
negative I-Not_AE_Candidate
at O
baseline O
was O
0.5 O
% O
in O
patients O
receiving O
SIMPONI O
induction O
and O
100 O
mg O
during O
maintenance O
compared O
with O
0 O
% O
in O
patients O
who O
received O
SIMPONI O
induction O
and O
placebo O
during O
maintenance O
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
. O

Injection O
Site O
Reactions O
In O
controlled O
Phase O
3 O
trials O
through O
Week O
16 O
in O
RA B-Not_AE_Candidate
, O
PsA B-Not_AE_Candidate
and O
AS B-Not_AE_Candidate
, O
6 O
% O
of O
SIMPONI-treated O
patients O
had O
injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
compared O
with O
2 O
% O
of O
control-treated O
patients O
. O

The O
majority O
of O
the O
injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
were O
mild O
and O
the O
most O
frequent O
manifestation O
was O
injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
erythema I-OSE_Labeled_AE
. O

In O
the O
controlled O
Phase O
2/3 O
trial O
through O
Week O
6 O
in O
UC B-Not_AE_Candidate
, O
3.4 O
% O
of O
SIMPONI-treated O
patients O
had O
injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
compared O
with O
1.5 O
% O
in O
control-treated O
patients O
. O

The O
majority O
of O
the O
injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
were O
mild O
and O
moderate O
and O
the O
most O
frequent O
manifestation O
was O
injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
erythema I-OSE_Labeled_AE
. O

In O
controlled O
Phase O
2 O
and O
3 O
trials O
in O
RA B-Not_AE_Candidate
, O
PsA B-Not_AE_Candidate
, O
AS B-Not_AE_Candidate
, O
and O
Phase O
2/3 O
UC B-Not_AE_Candidate
trials O
, O
no O
patients O
treated O
with O
SIMPONI O
developed O
anaphylactic B-NonOSE_AE
reactions I-NonOSE_AE
. O

Immunogenicity O
Antibodies B-OSE_Labeled_AE
to I-OSE_Labeled_AE
SIMPONI I-OSE_Labeled_AE
were O
detected O
in O
57 O
( O
4 O
% O
) O
of O
SIMPONI-treated O
patients O
across O
the O
Phase O
3 O
RA B-Not_AE_Candidate
, O
PsA B-Not_AE_Candidate
, O
and O
AS B-Not_AE_Candidate
trials O
through O
Week O
24 O
. O

Similar O
rates O
were O
observed O
in O
each O
of O
the O
3 O
indications O
. O

Patients O
who O
received O
SIMPONI O
with O
concomitant O
MTX O
had O
a O
lower O
proportion O
of O
antibodies B-OSE_Labeled_AE
to I-OSE_Labeled_AE
SIMPONI I-OSE_Labeled_AE
than O
patients O
who O
received O
SIMPONI O
without O
MTX O
( O
approximately O
2 O
% O
vs O
. O
7 O
% O
, O
respectively O
) O
. O

The O
presence O
of O
serum O
concentrations O
of O
golimumab O
can O
interfere O
with O
the O
detection O
of O
antibodies B-NonOSE_AE
to I-NonOSE_AE
SIMPONI I-NonOSE_AE
leading O
to O
inconclusive O
results O
. O

In O
UC B-Not_AE_Candidate
trials O
, O
34 O
( O
3 O
% O
) O
, O
341 O
( O
28 O
% O
) O
and O
823 O
( O
69 O
% O
) O
of O
SIMPONI-treated O
subjects O
were O
positive B-OSE_Labeled_AE
, I-OSE_Labeled_AE
negative I-OSE_Labeled_AE
and I-OSE_Labeled_AE
inconclusive I-OSE_Labeled_AE
for I-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
to I-OSE_Labeled_AE
SIMPONI I-OSE_Labeled_AE
, O
respectively O
. O

Treatment O
with O
concomitant O
immunomodulators O
( O
AZA O
, O
6-MP O
and O
MTX O
) O
resulted O
in O
a O
lower O
proportion O
of O
patients O
with O
antibodies B-OSE_Labeled_AE
to I-OSE_Labeled_AE
SIMPONI I-OSE_Labeled_AE
than O
patients O
receiving O
SIMPONI O
without O
immunomodulators O
( O
2 O
% O
vs O
. O
4 O
% O
, O
respectively O
) O
. O

Of O
the O
patients O
with O
a O
positive B-OSE_Labeled_AE
antibody I-OSE_Labeled_AE
response I-OSE_Labeled_AE
to I-OSE_Labeled_AE
SIMPONI I-OSE_Labeled_AE
in O
the O
Phase O
2 O
and O
3 O
trials O
, O
most O
were O
determined O
to O
have O
neutralizing B-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
to I-OSE_Labeled_AE
golimumab I-OSE_Labeled_AE
as O
measured O
by O
a O
cell-based O
functional O
assay O
. O

The O
small O
number O
of O
patients O
positive B-OSE_Labeled_AE
for I-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
to I-OSE_Labeled_AE
SIMPONI I-OSE_Labeled_AE
limits O
the O
ability O
to O
draw O
definitive O
conclusions O
regarding O
the O
relationship O
between O
antibodies B-NonOSE_AE
to I-NonOSE_AE
golimumab I-NonOSE_AE
and O
clinical O
efficacy O
or O
safety O
measures O
. O

The O
data O
above O
reflect O
the O
percentage O
of O
patients O
whose O
test O
results O
were O
considered O
positive B-NonOSE_AE
for I-NonOSE_AE
antibodies I-NonOSE_AE
to I-NonOSE_AE
SIMPONI I-NonOSE_AE
in O
an O
ELISA O
assay O
, O
and O
are O
highly O
dependent O
on O
the O
sensitivity O
and O
specificity O
of O
the O
assay O
. O

Additionally O
, O
the O
observed O
incidence O
of O
antibody B-NonOSE_AE
positivity I-NonOSE_AE
in O
an O
assay O
may O
be O
influenced O
by O
several O
factors O
including O
sample O
handling O
, O
timing O
of O
sample O
collection O
, O
concomitant O
medications O
, O
and O
underlying O
disease O
. O

For O
these O
reasons O
, O
comparison O
of O
the O
incidence O
of O
antibodies B-NonOSE_AE
to I-NonOSE_AE
SIMPONI I-NonOSE_AE
with O
the O
incidence O
of O
antibodies B-NonOSE_AE
to O
other O
products O
or O
results O
from O
different O
assays O
may O
be O
misleading O
. O

Other O
Adverse O
Reactions O
Table O
1 O
summarizes O
the O
adverse O
drug O
reactions O
that O
occurred O
at O
a O
rate O
of O
at O
least O
1 O
% O
in O
the O
SIMPONI O
+/- O
DMARD O
group O
and O
with O
a O
higher O
incidence O
than O
in O
the O
placebo O
+/- O
DMARD O
group O
during O
the O
controlled O
period O
of O
the O
5 O
pooled O
Phase O
3 O
trials O
through O
Week O
16 O
in O
patients O
with O
RA B-Not_AE_Candidate
, O
PsA B-Not_AE_Candidate
, O
and O
AS B-Not_AE_Candidate
. O

Table O
1 O
: O
Adverse O
Drug O
Reactions O
Reported O
by O
> O
= O
1 O
% O
of O
SIMPONI-Treated O
Patients O
and O
With O
a O
Higher O
Incidence O
Than O
Placebo-Treated O
Patients O
in O
the O
Phase O
3 O
Trials O
of O
RA O
, O
PsA O
, O
and O
AS O
through O
Week O
16Patients O
may O
have O
taken O
concomitant O
MTX O
, O
sulfasalazine O
, O
hydroxychloroquine O
, O
low O
dose O
corticosteroids O
( O
< O
= O
10 O
mg O
of O
prednisone/day O
or O
equivalent O
) O
, O
and/or O
NSAIDs O
during O
the O
trials O
) O
. O

SIMPONI O
+/- O
DMARDs O
Placebo O
+/- O
DMARDs O
Patients O
treated O
1659 O
639 O
Adverse O
Reaction O
Infections B-NonOSE_AE
and I-NonOSE_AE
infestations I-NonOSE_AE
Upper B-OSE_Labeled_AE
respiratory I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
( O
nasopharyngitis B-OSE_Labeled_AE
, O
pharyngitis B-OSE_Labeled_AE
, O
laryngitis B-OSE_Labeled_AE
, O
and O
rhinitis B-OSE_Labeled_AE
) O
16 O
% O
13 O
% O
Viral B-OSE_Labeled_AE
infections I-OSE_Labeled_AE
( O
such O
as O
influenza O
and O
herpes O
) O
5 O
% O
3 O
% O
Bronchitis B-OSE_Labeled_AE
2 O
% O
1 O
% O
Superficial B-OSE_Labeled_AE
fungal I-OSE_Labeled_AE
infections I-OSE_Labeled_AE
2 O
% O
1 O
% O
Sinusitis B-OSE_Labeled_AE
2 O
% O
1 O
% O
General B-NonOSE_AE
disorders I-NonOSE_AE
and I-NonOSE_AE
administration I-NonOSE_AE
site I-NonOSE_AE
conditions I-NonOSE_AE
Injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
( O
injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
erythema I-OSE_Labeled_AE
, O
urticaria O
, O
induration O
, O
pain O
, O
bruising O
, O
pruritus O
, O
irritation O
, O
paresthesia O
) O
6 O
% O
2 O
% O
Investigations B-NonOSE_AE
Alanine B-OSE_Labeled_AE
aminotransferase I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
4 O
% O
3 O
% O
Aspartate B-OSE_Labeled_AE
aminotransferase I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
3 O
% O
2 O
% O
Vascular B-NonOSE_AE
disorders I-NonOSE_AE
Hypertension B-OSE_Labeled_AE
3 O
% O
2 O
% O
Nervous B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
Dizziness B-OSE_Labeled_AE
2 O
% O
1 O
% O
Paresthesia B-OSE_Labeled_AE
2 O
% O
1 O
% O
Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
Constipation B-OSE_Labeled_AE
1 O
% O
< O
1 O
% O
Less O
Common O
Clinical O
Trial O
Adverse O
Drug O
Reactions O
Adverse O
drug O
reactions O
that O
occurred O
< O
1 O
% O
in O
SIMPONI-treated O
patients O
during O
the O
SIMPONI O
clinical O
trials O
that O
do O
not O
appear O
in O
the O
Warnings O
and O
Precautions O
section O
included O
the O
following O
events O
listed O
by O
system O
organ O
class O
: O
Infections B-NonOSE_AE
and I-NonOSE_AE
infestations I-NonOSE_AE
: O
Septic B-OSE_Labeled_AE
shock I-OSE_Labeled_AE
, O
atypical B-OSE_Labeled_AE
mycobacterial I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
pyelonephritis B-OSE_Labeled_AE
, O
arthritis B-OSE_Labeled_AE
bacterial I-OSE_Labeled_AE
, O
bursitis B-OSE_Labeled_AE
infective I-OSE_Labeled_AE
Neoplasms B-NonOSE_AE
benign I-NonOSE_AE
, I-NonOSE_AE
malignant I-NonOSE_AE
and I-NonOSE_AE
unspecified I-NonOSE_AE
: O
Leukemia B-OSE_Labeled_AE
Skin B-NonOSE_AE
and I-NonOSE_AE
subcutaneous I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
: O
Psoriasis B-OSE_Labeled_AE
( O
new O
onset O
or O
worsening O
, O
palmar/plantar O
and O
pustular O
) O
, O
vasculitis B-OSE_Labeled_AE
( I-OSE_Labeled_AE
cutaneous I-OSE_Labeled_AE
) O
Vascular B-NonOSE_AE
disorders I-NonOSE_AE
: O
Vasculitis B-OSE_Labeled_AE
( I-OSE_Labeled_AE
systemic I-OSE_Labeled_AE
) O
Other O
Clinical O
Trial O
Adverse O
Drug O
Reactions O
in O
Ulcerative O
Colitis O
Clinical O
Trials O
In O
the O
Phase O
2/3 O
trials O
in O
UC B-Not_AE_Candidate
evaluating O
1233 O
SIMPONI-treated O
patients O
, O
no O
new O
adverse O
drug O
reactions O
were O
identified O
and O
the O
frequency O
of O
adverse O
drug O
reactions O
was O
similar O
to O
the O
safety O
profile O
observed O
in O
patients O
with O
RA B-Not_AE_Candidate
, O
PsA B-Not_AE_Candidate
and O
AS B-Not_AE_Candidate
. O

6.2 O
Postmarketing O
Experience O
The O
following O
adverse O
reactions O
have O
been O
identified O
during O
post-approval O
use O
of O
golimumab O
. O

Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
SIMPONI O
exposure O
. O

Immune B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
: O
Serious O
systemic B-OSE_Labeled_AE
hypersensitivity I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
( O
including O
anaphylactic B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
) O
[ O
see O
Warnings O
and O
Precautions O
( O
5.11 O
) O
] O
, O
sarcoidosis B-OSE_Labeled_AE
Neoplasms B-NonOSE_AE
benign I-NonOSE_AE
, I-NonOSE_AE
malignant I-NonOSE_AE
and I-NonOSE_AE
unspecified I-NonOSE_AE
: O
Melanoma B-OSE_Labeled_AE
, O
Merkel B-OSE_Labeled_AE
cell I-OSE_Labeled_AE
carcinoma I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
Respiratory B-NonOSE_AE
, I-NonOSE_AE
thoracic I-NonOSE_AE
and I-NonOSE_AE
mediastinal I-NonOSE_AE
disorders I-NonOSE_AE
: O
Interstitial B-OSE_Labeled_AE
lung I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
Skin B-NonOSE_AE
and I-NonOSE_AE
subcutaneous I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
: O
Skin B-OSE_Labeled_AE
exfoliation I-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
, O
bullous B-OSE_Labeled_AE
skin I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE

